ReviewGenes & diseases2026
LRRC8A: A multifaceted regulator in cancer, neurological disorders, metabolic diseases and immune modulation.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells.International journal of molecular sciences · 2026Article
- Single-cell RNA sequencing data analysis reveals differential expressions of ion channels in immunity response to pulmonary COVID-19 infection.Biochemical and biophysical research communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leucine-rich repeat containing 8A (LRRC8A) is a member of the LRRC8 family, exhibiting broad expression across various tissues and cells in vertebrates. Like other LRRC8 family members, LRRC8A contributes to the formation of volume-regulated anion channels (VRACs), which are crucial for regulating cell volume and maintaining homeostasis. LRRC8A participates in diverse signaling pathways. Multiple studies have validated the links between LRRC8A dysregulation and neurological disorders, metabolic ailments, and tumors. This review provides a comprehensive overview of the regulatory mechanisms of LRRC8A in these pathologies. The primary goal was to assess the potential of LRRC8A as a therapeutic target for treating diseases and address key unresolved issues.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.